<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="153131">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02034890</url>
  </required_header>
  <id_info>
    <org_study_id>RMC-7350</org_study_id>
    <nct_id>NCT02034890</nct_id>
  </id_info>
  <brief_title>Intravesical Instillation of Hyaluronic Acid to Decrease Incidence of Urinary Tract Infection</brief_title>
  <official_title>Is Intra - Neobladder Installations of Hyaluronic Acid, Effective in Reducing Neobladder Orthotropic Reconstruction Post-operative Urinary Tract Infections?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rabin Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rabin Medical Center</source>
  <oversight_info>
    <authority>Israel: Ministry of Health</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective trial which includes instillation of intravesical hyaluronic acid in an attempt
      to reduce the incidence of urinary tract infections in patients after orthotopic neobladder
      reconstruction.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>March 2014</start_date>
  <primary_completion_date type="Anticipated">March 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>positive urinary culture</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>urinary tract infection</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Urinary Tract Infection</condition>
  <arm_group>
    <arm_group_label>hyaluronic acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>intravesical instillation of 40 mg of hyaluronic acid at 6 specific time points: 1,2,3 and 4 weeks postoperatively 2 and 3 months postoperatively</description>
  </arm_group>
  <arm_group>
    <arm_group_label>retrospective control patients</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>retrospective control patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hyaluronic Acid</intervention_name>
    <description>intravesical instillation of 40 mg of hyaluronic acid in 6 specific time points: 1,2,3 and 4 weeks postoperatively (After radical cystectomy and orthotopic neobladder reconstruction) 2 and 3 months postoperatively</description>
    <arm_group_label>hyaluronic acid</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients undergoing radical cystectomy and orthotopic neobladder reconstruction

        Exclusion Criteria:

          -  patients &lt;18 years and unwilling to participate in this study
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hanan Goldberg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rabin Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hanan Goldberg</last_name>
    <phone>972544315412</phone>
    <email>gohanan@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Urology department, Rabin Medical Center</name>
      <address>
        <city>Petach Tiqva</city>
        <zip>49100</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hanan Goldberg</last_name>
      <phone>972544315412</phone>
    </contact>
    <investigator>
      <last_name>Hanan Goldberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 10, 2014</lastchanged_date>
  <firstreceived_date>January 10, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rabin Medical Center</investigator_affiliation>
    <investigator_full_name>Hanan Goldberg</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>orthotopic neobladder</keyword>
  <keyword>urinary tract infection</keyword>
  <keyword>intravesical instillation</keyword>
  <keyword>hyaluronic acid</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Urinary Tract Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hyaluronic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
